President Donald Trump “has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” US Trade Representative Jamieson Greer said in a statement late Thursday. The move comes as a government overhaul of Germany’s health-insurance system, designed in part to reduce spending on drugs, makes its way through parliament in Berlin.






